Direxion Daily S&P Biotech Bear 3X ETF (LABD)
| Assets | $69.50M |
| Expense Ratio | 1.07% |
| PE Ratio | n/a |
| Shares Out | 4.66M |
| Dividend (ttm) | $0.94 |
| Dividend Yield | 6.25% |
| Ex-Dividend Date | Mar 24, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 2,736,549 |
| Open | 15.26 |
| Previous Close | 15.10 |
| Day's Range | 13.97 - 15.30 |
| 52-Week Low | 12.47 |
| 52-Week High | 101.00 |
| Beta | -2.45 |
| Holdings | 13 |
| Inception Date | May 28, 2015 |
About LABD
Fund Home PageThe Direxion Daily S&P Biotech Bear 3X ETF (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
104.57% of assets| Name | Symbol | Weight |
|---|---|---|
| Goldman Finl Sq Trsry Inst 506 | n/a | 47.59% |
| Dreyfus Govt Cash Man Ins | n/a | 40.64% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 10.65% |
| Dreyfus Trsry Securities Cash Mgmt | n/a | 5.76% |
| S&P Biotechnology Select Industry Index Swap | n/a | 1.84% |
| Citi Collateral | n/a | -0.00% |
| S&P Biotechnology Select Industry Index Swap | n/a | -0.11% |
| Barclays Collateral | n/a | -0.43% |
| S&P Biotechnology Select Industry Index Swap | n/a | -0.63% |
| Cash | n/a | -0.75% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2026 | $0.08539 | Mar 31, 2026 |
| Dec 23, 2025 | $0.22872 | Dec 31, 2025 |
| Sep 23, 2025 | $0.260 | Sep 30, 2025 |
| Jun 24, 2025 | $0.3696 | Jul 1, 2025 |
| Mar 25, 2025 | $0.5463 | Apr 1, 2025 |
| Dec 23, 2024 | $1.2639 | Dec 31, 2024 |
Performance
LABD had a total return of -80.31% in the past year, including dividends. Since the fund's inception, the average annual return has been -53.60%.
News
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push towa...
3 Bearish ETFs To Profit Bullish Counterparts With Elevated Short Interest
It's not just stocks that are made for shorting. Plenty of traders tap exchange-traded funds on the bearish side of things and do so for a variety of reasons.
These Are The Leveraged ETFs At Play When Trade War Worries Strike
The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.